Page 1025 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

2 References

27. Brink AJ, Richards GA, Schillack V, et al. Pharmacokinetics of 43. Boselli E, Breilh D, Rimmele T, et al. Pharmacokinetics and
once-daily dosing of ertapenem in critically ill patients with intrapulmonary concentrations of linezolid administered to
severe sepsis. Int J Antimicrob Agents. 2009;33:432-436. critically ill patients with ventilator-associated pneumonia. Crit
28. Collins VL, Marchaim D, Pogue JM, et al. Efficacy of ertapenem Care Med. 2005;33:1529-1533.
for treatment of bloodstream infections caused by extended- 44. Niederman MS. Treatment options for nosocomial pneumonia
spectrum-beta-lactamase-producing Enterobacteriaceae. due to MRSA. J Infect. 2009;59(suppl 1):S25-S31.
Antimicrob Agents Chemother. 2012;56:2173-2177. 45. Buerger C, Plock N, Dehghanyar P, et al. Pharmacokinetics of
29. Lee SY, Kuti JL, Nicolau DP. Cefepime pharmacodynamics in unbound linezolid in plasma and tissue interstitium of critically
patients with extended spectrum beta-lactamase (ESBL) and ill patients after multiple dosing using microdialysis. Antimicrob
non-ESBL infections. J Infect. 2007;54:463-468. Agents Chemother. 2006;50:2455-2463.
30. Crandon JL, Bulik CC, Kuti JL, et al. Clinical pharmacodynamics 46. Bhalodi AA, Papasavas PK, Tishler DS, et al. Pharmacokinetics
of cefepime in patients infected with Pseudomonas aeruginosa. of intravenous linezolid in moderately to morbidly obese adults.
Antimicrob Agents Chemother. 2010;54:1111-1116. Antimicrob Agents Chemother. 2013;57(3):1144-1149.
31. Craig WA. Optimizing aminoglycoside use. Crit Care Clin. 47. French G. Safety and tolerability of linezolid. J Antimicrob
2011;27:107-121. Chemother. 2003;51(suppl 2):ii45-ii53.
32. Rea RS, Capitano B, Bies R, et al. Suboptimal aminogly- 48. Peterson LR. A review of tigecycline—the first glycylcycline.
coside dosing in critically ill patients. Ther Drug Monit. Int J Antimicrob Agents. 2008;32(suppl 4):S215-S222.
2008;30:674-681. 49. Meagher AK, Ambrose PG, Grasela TH, et al. Pharmacokinetic/
33. Nicolau DP, Freeman CD, Belliveau PP, et al. Experience with a pharmacodynamic profile for tigecycline-a new glycylcycline
once-daily aminoglycoside program administered to 2,184 adult antimicrobial agent. Diagn Microbiol Infect Dis. 2005;52:165-171.
patients. Antimicrob Agents Chemother. 1995;39:650-655. 50. Freire AT, Melnyk V, Kim MJ, et al. Comparison of tigecycline
34. Bergen PJ, Li J, Nation RL. Dosing of colistin-back to basic with imipenem/cilastatin for the treatment of hospital-acquired
PK/PD. Curr Opin Pharmacol. 2011;11:464-469. pneumonia. Diagn Microbiol Infect Dis. 2010;68:140-151.
35. Imberti R, Cusato M, Villani P, et al. Steady-state pharmacoki- 51. Ramirez J, Dartois N, Gandjini H, et al. Randomized phase 2
netics and BAL concentration of colistin in critically Ill patients trial to evaluate the clinical efficacy of two high-dosage tige-
after IV colistin methanesulfonate administration. Chest. 2010; cycline regimens versus imipenem-cilastatin for treatment of
138:1333-1339. hospital-acquired pneumonia. Antimicrob Agents Chemother.
36. Markou N, Markantonis SL, Dimitrakis E, et al. Colistin serum 2013;57:1756-1762.
concentrations after intravenous administration in critically ill 52. Rodvold KA, Gotfried MH, Cwik M, et al. Serum, tissue and
patients with serious multidrug-resistant, gram-negative bacilli body fluid concentrations of tigecycline after a single 100 mg
infections: a prospective, open-label, uncontrolled study. Clin dose. J Antimicrob Chemother. 2006;58:1221-1229.
Ther. 2008;30:143-151. 53. Steenbergen JN, Alder J, Thorne GM, et al. Daptomycin: a lipo-
37. Garonzik SM, Li J, Thamlikitkul V, et al. Population pharma- peptide antibiotic for the treatment of serious Gram-positive
cokinetics of colistin methanesulfonate and formed colistin in infections. J Antimicrob Chemother. 2005;55:283-288.
critically ill patients from a multicenter study provide dosing 54. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines
suggestions for various categories of patients. Antimicrob Agents by the infectious diseases society of america for the treatment of
Chemother. 2011;55:3284-3294. methicillin-resistant Staphylococcus aureus infections in adults
38. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic and children. Clin Infect Dis. 2011;52:e18-e55.
monitoring of vancomycin in adult patients: a consensus 55. Bubalo JS, Munar MY, Cherala G, et al. Daptomycin pharma-
review of the American Society of Health-System Pharmacists, cokinetics in adult oncology patients with neutropenic fever.
the Infectious Diseases Society of America, and the Society Antimicrob Agents Chemother. 2009;53:428-434.
of Infectious Diseases Pharmacists. Am J Health Syst Pharm.
2009;66:82-98. 56. Donovan BJ, Mohr JF, Knapp AG, et al. Decreasing the prob-
ability of creatine phosphokinase elevations: clinical consider-
39. van Hal SJ, Lodise TP, Paterson DL. The clinical signifi- ations for daptomycin dosing in obese patients. Clin Infect Dis.
cance of vancomycin minimum inhibitory concentration in 2010;51:989; author reply -90.
Staphylococcus aureus infections: a systematic review and
meta-analysis. Clin Infect Dis. 2012;54:755-771. 57. Zhanel GG, Walkty A, Vercaigne L, et al. The new fluoroquino-
lones: a critical review. Can J Infect Dis. 1999;10:207-238.
40. Chang HJ, Hsu PC, Yang CC, et al. Influence of teicoplanin MICs
on treatment outcomes among patients with teicoplanin-treated 58. Zhanel GG, Ennis K, Vercaigne L, et al. A critical review of
methicillin-resistant Staphylococcus aureus bacteraemia: a the fluoroquinolones: focus on respiratory infections. Drugs.
hospital-based retrospective study. J Antimicrob Chemother. 2012; 2002;62:13-59.
67:736-741. 59. Forrest A, Nix DE, Ballow CH, et al. Pharmacodynamics of
41. Chen KY, Chang HJ, Hsu PC, et al. Relationship of teicoplanin intravenous ciprofloxacin in seriously ill patients. Antimicrob
MICs to treatment failure in teicoplanin-treated patients with Agents Chemother. 1993;37:1073-1081.
methicillin-resistant Staphylococcus aureus pneumonia. J Microbiol 60. Preston SL, Drusano GL, Berman AL, et al. Pharmacodynamics
Immunol Infect. 2013;46(3):210-216. of levofloxacin: a new paradigm for early clinical trials. JAMA.
42. Craig WA. Basic pharmacodynamics of antibacterials with clinical 1998;279:125-129.
applications to the use of beta-lactams, glycopeptides, and line- 61. Ambrose PG, Grasela DM, Grasela TH, et al. Pharmacodynamics
zolid. Infect Dis Clin North Am. 2003;17:479-501. of fluoroquinolones against Streptococcus pneumoniae in

Section05-O-ref.indd 2 1/20/2015 4:51:15 PM